Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage
Status:
Withdrawn
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical effect of esmolol treatment on cardiac
function and electrophysiology; to assess the effects of esmolol treatment on serum
adrenergic and cardiac biomarkers; to explore the safety of esmolol treatment shortly after
subarachnoid hemorrhage (SAH). Patients will be followed for a maximum of 1 month after the
index SAH. The primary outcome will be change in systolic function - ejection fraction by
Simpson's rule (baseline versus Day 7 +/- 2 after SAH).